Semaglutide: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or a specific compound. Nothing here is a protocol, a recommendation or an endorsement. The aim is narrower: to summarise what the published literature on semaglutide actually reported, module by module, and to be explicit about where that literature stops.

Module 1 — What Semaglutide Is and How It Has Been Studied

Definition and class. Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone, and it belongs to the drug class known as GLP-1 receptor agonists. A 2019 review in Frontiers in Endocrinology traced the discovery and development programme that produced first liraglutide and then semaglutide, describing how amino-acid substitution and attachment of a fatty-acid side chain were used to slow degradation and extend circulating time relative to native GLP-1 (PMID 31031702).

Origin. The molecule is not extracted from an animal source; it is an engineered analogue built on the human GLP-1 backbone, and the same 2019 review described the structural modification strategy — including albumin-binding acylation — that distinguished semaglutide from earlier incretin analogues (PMID 31031702).

Forms studied. A 2024 systematic review of clinical pharmacokinetics in Drug Design, Development and Therapy covered both the subcutaneous once-weekly formulation and an oral tablet formulation, noting that the two routes have been characterised separately in human studies (PMID 38952487). A 2022 paper in the Journal of Investigative Medicine described the subcutaneous 2.4 mg once-weekly product marketed as Wegovy for chronic weight management (PMID 34706925).

How the evidence base is built

• Preclinical rodent work — a 2020 study in JCI Insight examined body-weight lowering in rodents and the neural pathways involved (PMID 32213703).
• Randomised trials pooled in meta-analysis — a 2022 systematic review and meta-analysis assessed weight-loss efficacy and safety in obesity without diabetes (PMID 36578889).
• Long-term trial analysis — a 2024 Nature Medicine report described long-term weight-loss effects in the SELECT trial population (PMID 38740993).
• Narrative and safety reviews — including a 2021 safety review (PMID 34305810) and reviews of use in overweight and obesity (PMID 36254579, PMID 34942372).
• Case reports — single-patient publications such as a report of semaglutide-associated kidney injury (PMID 39258261) and a report of hyperemesis gravidarum (PMID 38249445).

Limits of the evidence in Module 1. Definitional and developmental accounts are descriptive, not experimental; the 2019 development review summarised a programme rather than testing a hypothesis (PMID 31031702). Study populations in the pooled and long-term analyses were selected by trial entry criteria, so the literature describes those enrolled groups and not people in general.

Module 2 — Mechanism as Described in the Literature

Receptor target. Reviews describe semaglutide as an agonist at the GLP-1 receptor, and a 2023 review in Trends in Cardiovascular Medicine summarised the mechanism in obesity as reduced appetite and energy intake alongside effects on glucose-dependent insulin secretion and gastric emptying (PMID 34942372). A 2023 review in Diabetes, Obesity & Metabolism similarly framed appetite regulation as the mechanism invoked for weight change in overweight and obesity (PMID 36254579).

Why it lasts longer than native GLP-1. The 2019 development review attributed the extended duration of action to structural changes, including fatty-acid acylation that promotes albumin binding and resistance to enzymatic degradation (PMID 31031702).

Central nervous system work. The 2020 rodent study reported that semaglutide lowered body weight through distributed neural pathways rather than through a single discrete brain region, and researchers interpreted the findings as evidence that multiple GLP-1 receptor populations contribute to the body-weight effect (PMID 32213703).

Limits of the evidence in Module 2. Mechanistic detail comes largely from animal work, and the 2020 rodent study mapped pathways in rodents, not humans (PMID 32213703). Review articles describe mechanism as consensus interpretation rather than as a measured endpoint (PMID 36254579). A plausible mechanism does not establish that any individual outcome will follow.

Module 3 — Reported Outcomes by Study

The table below summarises models, endpoints and the direction of reported findings. It describes what researchers measured; it does not forecast outcomes for anyone.

Reading the outcome literature carefully

The 2022 meta-analysis pooled randomised comparisons in adults with obesity but without diabetes and reported both a weight-loss signal and a safety signal in the same analysis, which is why efficacy and tolerability are best read together rather than separately (PMID 36578889). The 2024 long-term analysis extended the observation window well beyond the length of most weight-loss trials and reported durability of the weight change in that trial population (PMID 38740993). Narrative reviews from 2022 and 2023 placed these findings in the context of obesity pharmacotherapy generally (PMID 34942372, PMID 36254579).

Limits of the evidence in Module 3. Trial averages are not individual outcomes; the pooled estimate in the 2022 meta-analysis describes group means across studies of differing design (PMID 36578889). Trials were conducted alongside lifestyle programmes and with protocol-specified monitoring, and the 2025 heart-failure comparison addressed one specific clinical population rather than a general one (PMID 40886075). No study reported here promises a result for any reader.

Module 4 — Semaglutide Side Effects: What Studies Report

Gastrointestinal complaints dominate the published record. A 2021 safety review in Frontiers in Endocrinology reported that gastrointestinal events — nausea, vomiting, diarrhoea and constipation — were the most commonly observed adverse effects across the semaglutide programme (PMID 34305810). The 2022 meta-analysis in obesity without diabetes likewise reported a higher frequency of gastrointestinal adverse events with semaglutide than with placebo (PMID 36578889), and the 2022 Wegovy paper described gastrointestinal intolerance as the adverse-event category most relevant to the weight-management product (PMID 34706925).

Events discussed in safety reviews

• Discontinuation and dose-related tolerability — the 2021 safety review discussed adverse events leading to treatment discontinuation and how they were handled in the trial programme (PMID 34305810).
• Pancreatic, gallbladder, retinal and thyroid safety questions — the same 2021 review surveyed the safety topics raised across the GLP-1 receptor agonist class and the semaglutide trials specifically (PMID 34305810), and the 2023 obesity review also addressed tolerability and safety considerations in weight management (PMID 36254579).
• Kidney injury — a 2024 report in Clinical Kidney Journal described semaglutide-associated kidney injury, and the authors discussed the relationship between gastrointestinal fluid losses and renal harm (PMID 39258261).
• Severe vomiting in pregnancy — a 2024 case report in JCEM Case Reports described semaglutide-induced hyperemesis gravidarum in a single patient (PMID 38249445).

Limits of the evidence in Module 4. Case reports describe one patient and cannot establish how often an event occurs; the 2024 kidney-injury report and the 2024 hyperemesis report are individual observations, not incidence estimates (PMID 39258261, PMID 38249445). Trial safety data reflect supervised settings with eligibility screening, and the 2021 review noted that rarer outcomes require longer or larger datasets than individual trials provide (PMID 34305810). Adverse-event frequency in the literature is not a prediction for any individual.

Module 5 — Pharmacokinetics Where Data Exist

Duration of exposure. The 2024 systematic review of clinical pharmacokinetics reported a long elimination half-life in the range of about one week, which is the basis for once-weekly subcutaneous administration in the clinical programme (PMID 38952487). The 2019 development review attributed that prolonged exposure to albumin binding and reduced susceptibility to degradation (PMID 31031702).

Accumulation to steady state. Because of the long half-life, the 2024 pharmacokinetic review described concentrations rising over several weekly administrations before reaching steady state, and researchers also summarised variability across populations studied (PMID 38952487).

Oral versus subcutaneous. The 2024 pharmacokinetic review covered oral administration separately, noting that absorption of the oral formulation is low and is the main pharmacokinetic difference from the injected route (PMID 38952487).

Limits of the evidence in Module 5. Pharmacokinetic parameters are population averages derived from sampled study cohorts, and the 2024 review itself discussed between-study and between-population variability (PMID 38952487). Pharmacokinetic data describe drug exposure only; exposure is not an outcome, and the reviews did not translate concentration into a clinical effect for an individual (PMID 31031702).

Module 6 — Regulatory Status, Stated Factually

Approved products. Semaglutide is the active ingredient in prescription products authorised by regulators in the United States, the European Union and other jurisdictions: a once-weekly subcutaneous injection and an oral tablet for type 2 diabetes, and a separate higher-dose subcutaneous product for chronic weight management. The 2022 Journal of Investigative Medicine paper described the 2.4 mg once-weekly weight-management product and its approval context (PMID 34706925), and the 2023 obesity review discussed its place among approved anti-obesity medications (PMID 36254579). Approved products are dispensed by prescription, with labelling, indications, contraindications and warnings set by the reviewing agency.

Research-use-only material. Peptide material sold and labelled “for research use only” is a laboratory reagent category. Such material is not an approved drug, is not reviewed by a regulator for identity, purity, sterility or potency, and is labelled as not for human or veterinary use. The published clinical literature summarised in this course — including the trial and pharmacokinetic reports cited above — was generated with pharmaceutical-grade material under regulated protocols (PMID 38952487), so findings from those studies cannot be assumed to apply to reagent-grade material of unknown provenance.

Compounding. In the United States, compounding pharmacies may prepare medications under specific statutory conditions; the US Food and Drug Administration has stated publicly that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness or quality before marketing, and it has issued communications about compounded GLP-1 products, including reports of dosing errors and the use of salt forms of the active ingredient. Regulatory positions and drug-shortage listings change over time and differ by country and, within the United States, by state. This section is a factual summary of publicly stated regulatory positions and is not legal advice.

Limits of the evidence in Module 6. Regulatory approval attaches to a specific product, formulation, strength and indication studied in the sponsor's programme, as described for the weight-management product in 2022 (PMID 34706925). Approval status is not a measure of individual benefit, and the peer-reviewed literature cited here evaluated the studied products rather than every semaglutide-containing preparation in circulation (PMID 34305810).

What the Studies Did Not Test

Reading the verified literature closely, several things are absent rather than negative:

• Use outside studied populations. The 2022 meta-analysis enrolled adults with obesity without diabetes, so it did not address people who fall outside those criteria (PMID 36578889).
• Cosmetic or performance goals. No cited study measured athletic performance, body composition for aesthetic purposes, or use in people without a metabolic indication (PMID 36254579).
• Pregnancy. The only pregnancy-related publication among the verified papers was a single case report of hyperemesis gravidarum, which is not a safety evaluation in pregnancy (PMID 38249445).
• Combinations and self-directed regimens. The cited trials and reviews studied defined single-agent regimens under supervision; they did not evaluate unsupervised use, combinations with other peptides, or non-approved preparations (PMID 34305810).
• Indefinite duration. Even the longest analysis cited here described a defined multi-year observation period in a specific trial, not lifetime use (PMID 38740993).
• Head-to-head certainty across agents. The 2025 JAMA comparison addressed one population with heart failure with preserved ejection fraction and did not settle comparative questions in other groups (PMID 40886075).

Again, this course is educational and descriptive. Decisions about any prescription medicine belong to a licensed clinician who can weigh an individual's history, other medications and monitoring needs.

References

• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Semaglutide lowers body weight in rodents via distributed neural pathways (JCI Insight, 2020)
• Safety of Semaglutide (Frontiers in Endocrinology, 2021)
• Wegovy (semaglutide): a new weight loss drug for chronic weight management (Journal of Investigative Medicine, 2022)
• Semaglutide for the treatment of obesity (Trends in Cardiovascular Medicine, 2023)
• Semaglutide for the treatment of overweight and obesity: A review (Diabetes, Obesity & Metabolism, 2023)
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• Semaglutide-induced Hyperemesis Gravidarum (JCEM Case Reports, 2024)
• Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (Nature Medicine, 2024)
• Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)
• Semaglutide-associated kidney injury (Clinical Kidney Journal, 2024)
• Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (JAMA, 2025)